Patent US4086350A successfully refreshed from Google Patents.
US4086350A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical compositions and method of producing anti-psychotic activity without extrapyramidal symptoms
Assignee: GlaxoSmithKline LLC
•
Filing: 1976-02-05
•
Granted: 1978-04-25
•
Expires: 1996-02-05
Abstract
Abstract Tricyclic piperidylidene derivatives administered internally to an animal host, in therapeutically effective amounts, produce antipsychotic activity without extrapyramidal symptoms. Certain of the active ingredients are novel compounds per se.
Inventors
- 👤 Charles Leon Zirkle
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 10:15
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61K31/445
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
61 words
A compound represented by one of the formulas: ##STR2## wherein, for formula I: when Y represents oxygen, X is 2-fluoro, Z is 6-chloro and R is methyl; when Y represents sulfur, X is 2-cyano, Z is hydrogen and R is methyl; and for formula II: when X is hydrogen, Z is 9-chloro, or a nontoxic pharmaceutically acceptable acid addition salt thereof.
Claim 2
Dependent Claim
61 words
A compound represented by one of the formulas: ##STR2## wherein, for formula I: when Y represents oxygen, X is 2-fluoro, Z is 6-chloro and R is methyl; when Y represents sulfur, X is 2-cyano, Z is hydrogen and R is methyl; and for formula II: when X is hydrogen, Z is 9-chloro, or a nontoxic pharmaceutically acceptable acid addition salt thereof.
Claim 3
Dependent Claim
24 words
A compound according to claim 1, of formula I, in which Y is oxygen, X is 2-fluoro, Z is 6-chloro and R is methyl.
Claim 4
Dependent Claim
24 words
A compound according to claim 1, of formula I, in which Y is sulfur, X is 2-cyano, Z is hydrogen and R is methyl.
Claim 5
Dependent Claim
18 words
A compound according to claim 1, of formula II, in which X is hydrogen and Z is 9-chloro.
Claim 6
Dependent Claim
50 words
A pharmaceutical composition having antipsychotic activity without producing extrapyramidal symptoms in dosage unit form which comprises a pharmaceutically carrier and a compound selected from among 4-(2-chloro-9-xanthenylidene)-1-methylpiperidine, 4-(6-chloro-2-fluoro-9-xanthenylidene)-1-methylpiperidine, 4-(2-cyano-9-thioxanthenylidene)-1-methylpiperidine and 4-(9-chloro-11(6H)-dibenz[b,e]oxepinylidene)-1-methylpiperidine, or a nontoxic pharmaceutically acceptable acid addition salt of said compound, in a nontoxic amount sufficient to produce said activity.
Claim 7
Dependent Claim
50 words
A pharmaceutical composition having antipsychotic activity without producing extrapyramidal symptoms in dosage unit form which comprises a pharmaceutically carrier and a compound selected from among 4-(2-chloro-9-xanthenylidene)-1-methylpiperidine, 4-(6-chloro-2-fluoro-9-xanthenylidene)-1-methylpiperidine, 4-(2-cyano-9-thioxanthenylidene)-1-methylpiperidine and 4-(9-chloro-11(6H)-dibenz[b,e]oxepinylidene)-1-methylpiperidine, or a nontoxic pharmaceutically acceptable acid addition salt of said compound, in a nontoxic amount sufficient to produce said activity.
Claim 8
Dependent Claim
13 words
A pharmacuetical composition according to claim 5 in which the compound is 4-(2-chloro-9-xanthenylidene)-1-methylpiperidine.
Claim 9
Dependent Claim
19 words
A pharmaceutical composition according to claim 6 in which the compound is in the form of a methanesulfonate salt.
Claim 10
Dependent Claim
28 words
A pharmaceutical composition according to claim 5 in which the active ingredient is in an amount selected from about 1 mg. to about 300 mg. per dosage unit.
Claim 11
Dependent Claim
28 words
A pharmaceutical composition according to claim 5 in which the active ingredient is in an amount selected from about 5 mg. to about 200 mg. per dosage unit.
Claim 12
Independent Claim
100 words
A method of producing antipsychotic activity without extrapyramidal symptoms which comprises administering internally to an animal in need of such activity a therapeutically effective amount of a compound represented by one of the formulas: ##STR3## wherein, for formula I: when Y represents oxygen, X is 2-chloro, Z is hydrogen and R is methyl; when Y represents sulfur, X is 2-cyano, Z is hydrogen and R is methyl; when Y represents oxygen, X is 2-fluoro, Z is 6-chloro and R is methyl; for formula II: when X is hydrogen, Z is 9-chloro, or a nontoxic pharmaceutically acceptable acid addition salt thereof.
Claim 13
Independent Claim
100 words
A method of producing antipsychotic activity without extrapyramidal symptoms which comprises administering internally to an animal in need of such activity a therapeutically effective amount of a compound represented by one of the formulas: ##STR3## wherein, for formula I: when Y represents oxygen, X is 2-chloro, Z is hydrogen and R is methyl; when Y represents sulfur, X is 2-cyano, Z is hydrogen and R is methyl; when Y represents oxygen, X is 2-fluoro, Z is 6-chloro and R is methyl; for formula II: when X is hydrogen, Z is 9-chloro, or a nontoxic pharmaceutically acceptable acid addition salt thereof.
Claim 14
Dependent Claim
12 words
A method according to claim 10 in which the compound is 4-(2-chloro-9-xanthenylidene)-1-methylpiperidine.
Claim 15
Dependent Claim
18 words
A method according to claim 11 in which the compound is in the form of a methanesulfonate salt.
Claim 16
Dependent Claim
20 words
A method according to claim 10 in which the compound is administered with a pharmaceutical carrier in dosage unit form.
Claim 17
Dependent Claim
12 words
A method according to claim 13 in which the administration is orally.
Claim 18
Dependent Claim
12 words
A method according to claim 13 in which the administration is intramuscularly.
Claim 19
Dependent Claim
26 words
A method according to claim 13 in which an active, nontoxic quantity selected from about 1 mg. to about 300 mg. of the compound is administered.
Claim 20
Dependent Claim
25 words
A method according to claim 10 in which a daily dosage selected from about 2 mg. to about 900 mg. of the compound is administered.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-04-24 | 1981-10-24 | 1982-04-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-04-24 | 1985-10-24 | 1986-04-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-04-24 | 1989-10-24 | 1990-04-25 | $7700.00 | Window Closed / Lapsed |